United Therapeutics Corporation UTHR NASDAQ

United Therapeutics Corporation (UTHR) generated $346.2M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $172.9M, free cash flow was $173.3M.

Free cash flow margin was 21.9% of revenue. Cash conversion ratio was 0.95x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (71/100, Pass) — $173.3M (21.9% margin) supports a durable competitive advantage
• INCOME (100/100) — Cash conversion ratio was 0.95x suggests some earnings are non-cash items

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.